Study of NanoDOX Hydrogel vs Placebo for Dehisced Surgical Wounds

Inclusion Criteria: * Be 18 years of age or older * Women of childbearing potential must have a negative urine pregnancy test at screening and at baseline, and: * Agree to use a double-barrier method of contraception during their participation in this study; * condoms (with spermicide) and hormonal contraceptives OR * condoms (with spermicide) and intrauterine device OR * intrauterine device and hormonal contraceptives OR * Abstains from sexual intercourse during their participation in this study OR * Is with a same-sex partner and does not participate in bisexual activities where there is a risk of becoming pregnant * Have a full-thickness dehisced surgical wound that is between 1.2cm2 and 4 cm2 at initial screening * Be able to apply study drug to their wound, or have a reliable and capable caregiver do it * Subjects will have adequate blood flow to the wound as defined by transcutaneous oxygen tension (TcpO2) of \>30mmHg recorded over intact epidermis at the dehisced surgical wound margin * Non-infected (Quantitative bacterial count of \< 1.0 x 105 cfu) Exclusion Criteria: * Less than 18 years of age * Pregnant or lactating woman or a female of childbearing potential who is not practicing acceptable form of birth control * Allergic to tetracycline, minocycline, demeclocycline, or any other known tetracycline derivative * Tested positive for a doxycycline-resistant infection * Have undergone treatment with system corticosteroid or immunosuppressive therapy in the past 2 months * Currently undergoing dialysis for renal failure * Have participated in another clinical research trial within the last 30 days * Subject has wounds resulting from any cause other than surgical intervention (diabetes, electrical burn, arterial insufficiency, chemical or radiation insult) * Active or previous (within 60 days prior to the study screening visit) chemotherapy * Active or previous (within 60 days prior to the study screening visit) radiation to the affected wound area to be treated by investigational drug or placebo * Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits * The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements standard-of-care self-care requirements, and all study-related follow up visit requirements * History of sickle cell anemia * History of infection with Human Immunodeficiency Virus * History of other immunodeficiency disorders * Severe anemia - Hgb \< 10 g/dL (males) or \< 9 g/dL (females) * Severe malnutrition (Albumin \< 3.0 gm/dl; \> 10% weight loss in preceding 6 weeks) * Subjects that the Investigators deems unstable and/or require intensive monitoring